Date: 2015-08-07
Type of information: Private placement
Company: Santhera Pharmaceuticals (Switzerland)
Investors:
Amount: CHF 27.7 Million (€ 25.8 million)
Funding type: private placement
Planned used: Last June the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation under exceptional circumstances for Raxone®, intended for the treatment of visual impairment in patients with Leber’s Hereditary Optic Neuropathy (LHON). The proceeds will be used to finance the commercial launch of Raxone® in Leber\'s Hereditary Optic Neuropathy (LHON) in Europe.
Others: * On August 7, 2015, Santhera Pharmaceuticals announced that it has completed the sale of 300,000 registered shares of common stock yielding an aggregate income of CHF 27.7 million (€ 25.8 million). The newly created shares with a par value of CHF 1.00 were issued from the Company\'s conditional capital and were sold by the independent broker Kepler Chevreux within four days (August 3 to 6) at an average price of CHF 92.38 per share. As of today, Santhera has 5.51 million shares outstanding.
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases - Ophtalmological diseases
